Beam Therapeutics Inc. Operating Lease, Payments
Beam Therapeutics Inc. (BEAM) reported Operating Lease, Payments of $24.43 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-24
- Beam Therapeutics Inc. operating lease, payments for the quarter ending 2022-12-31 was $5.00M, a 13.29% increase year-over-year.
- Beam Therapeutics Inc. operating lease, payments for the quarter ending 2022-09-30 was $4.60M, a 50.52% increase year-over-year.
- Beam Therapeutics Inc. operating lease, payments for the quarter ending 2022-06-30 was $4.95M, a 114.07% increase year-over-year.
- Beam Therapeutics Inc. operating lease, payments for the quarter ending 2022-03-31 was $4.51M, a 167.60% increase year-over-year.
- Beam Therapeutics Inc. operating lease, payments for fiscal 2025 was $24.43M, a 2.21% decline from fiscal 2024.
- Beam Therapeutics Inc. operating lease, payments for fiscal 2024 was $24.98M, a 10.52% increase from fiscal 2023.
- Beam Therapeutics Inc. operating lease, payments for fiscal 2023 was $22.60M, a 18.64% increase from fiscal 2022.
- Beam Therapeutics Inc. operating lease, payments for fiscal 2022 was $19.05M, a 66.22% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $24.43M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $24.98M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $22.60M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $9.60M derived: sum of 2 quarters · filed 2025-02-25 | $14.54M derived: sum of 3 quarters · filed 2025-02-25 | $19.05M 10-K · filed 2025-02-25 |
| 2022-09-30 | $4.60M 10-Q · filed 2022-11-07 | $9.55M derived: sum of 2 quarters · filed 2022-11-07 | $14.06M 10-Q · filed 2022-11-07 | $18.47M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $4.95M 10-Q · filed 2022-08-09 | $9.45M 10-Q · filed 2022-08-09 | $13.86M derived: sum of 3 quarters · filed 2024-02-27 | $16.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $4.51M 10-Q · filed 2022-05-09 | $8.92M derived: sum of 2 quarters · filed 2024-02-27 | $11.98M derived: sum of 3 quarters · filed 2024-02-27 | $14.29M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $7.47M derived: sum of 2 quarters · filed 2024-02-27 | $9.78M derived: sum of 3 quarters · filed 2024-02-27 | $11.46M 10-K · filed 2024-02-27 |
| 2021-09-30 | $3.06M 10-Q · filed 2022-11-07 | $5.37M derived: sum of 2 quarters · filed 2022-11-07 | $7.05M 10-Q · filed 2022-11-07 | $8.83M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.31M 10-Q · filed 2022-08-09 | $4.00M 10-Q · filed 2022-08-09 | $5.77M derived: sum of 3 quarters · filed 2023-02-28 | $7.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.69M 10-Q · filed 2022-05-09 | $3.46M derived: sum of 2 quarters · filed 2023-02-28 | $5.48M derived: sum of 3 quarters · filed 2023-02-28 | $7.07M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.79M derived: sum of 2 quarters · filed 2023-02-28 | $5.39M derived: sum of 3 quarters · filed 2023-02-28 | $6.91M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.01M 10-Q · filed 2021-11-08 | $3.61M derived: sum of 2 quarters · filed 2021-11-08 | $5.13M 10-Q · filed 2021-11-08 | $7.18M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.59M 10-Q · filed 2021-08-10 | $3.12M 10-Q · filed 2021-08-10 | $5.16M derived: sum of 3 quarters · filed 2022-02-28 | $6.37M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.52M 10-Q · filed 2021-05-11 | $3.57M derived: sum of 2 quarters · filed 2022-02-28 | $4.77M derived: sum of 3 quarters · filed 2022-02-28 | $5.73M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.25M derived: sum of 2 quarters · filed 2022-02-28 | $4.20M derived: sum of 3 quarters · filed 2022-02-28 | $4.95M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.20M 10-Q · filed 2020-11-10 | $2.16M derived: sum of 2 quarters · filed 2020-11-10 | $2.91M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $954.00K 10-Q · filed 2020-08-12 | $1.70M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $748.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |